Abstract:Background:Plasma-derived β-amyloid, tau, and neurodegeneration (ATN) biomarkers can accurately diagnose Alzheimer's disease (AD) and predict its progression. Few studies have investigated the relationship between plasma biomarkers and changes in plasma inflammatory markers in clinically diagnosed AD.Methods:Seventy-four participants were recruited, including 30 mild-to-moderate AD dementia patients and 44 normal controls (NC). All participants underwent neuropsychological testing and blood sampling for biomarker testing. AD was clinically diagnosed according to the National Institute on Aging-Alzheimer's Association (NIA-AA) core criteria and required age-mismatched hippocampal atrophy. We performed Single Molecule Array (Simoa), an ultra-sensitive enzyme-linked immunosorbent assay (ELISA), to examine plasma ATN markers, including β-amyloid (Aβ) 40, Aβ42, p-tau181, total (t)-tau, neurofilament protein light chain (NfL), and inflammatory factors (TNF-α, IL-1β, IL-6, and IL-8).Results:The level of the plasma Aβ42/Aβ40 ratio was significantly declined and the levels of the plasma p-tau181, NfL and TNF-α were significantly higher in the AD group than the NC group, but there was no significant difference in the levels of plasma t-tau, IL-1β, IL-6, and IL-8 between the AD and NC groups. The levels of plasma p-tau181, NfL, Aβ42/Aβ40 ratio, and TNF-α were all associated with impairments in multiple cognitive domains. Among them, the plasma Aβ42/Aβ40 ratio, and the p-tau181 and TNF-α levels were associated with impairments in global cognition, memory, and visuospatial abilities, but not with executive function, only plasma NfL level was associated with executive function. Plasma NfL showed higher diagnostic performance in AD than in NC individuals (AUC = 0.833). A combined diagnostic prediction model of plasma Aβ42/Aβ40 ratio, p-tau 181, and NfL had the highest value than each factor alone (AUC = 0.902),with a sensitivity and specificity of 0.867 and 0.886, respectively.Conclusion:The levels of plasma ATN biomarkers (Aβ42/Aβ40 ratio, p-tua181, and NfL) were significantly changed in clinically diagnosed AD patients and they all associated with different domains of cognitive impairment. Plasma ATN biomarkers better differentiate mild-to-moderate AD dementia from NC when they are incorporated into diagnostic models together rather than individually. Plasma ATN biomarkers have the potential to be a screening tool for AD. However, the expression of inflammatory factors in AD patients requires further research.

Comparison of Serum Triiodothyronine with Biomarkers for Alzheimer’s Disease Continuum in Euthyroid Subjects

Diagnostic Value of Isolated Plasma Biomarkers and Its Combination in Neurodegenerative Dementias: A Multicenter Cohort Study

Identification of Candidate Biomarkers of Alzheimer's Disease Via Multiplex Cerebrospinal Fluid and Serum Proteomics.

Associations of thyroid hormone serum levels with in-vivo Alzheimer's disease pathologies

Clinical Significance of Determination of Serum Thyroid Hormones in Patients with Alzheimer Disease

Moderation of thyroid hormones for the relationship between amyloid and tau pathology

Low levels of free triiodothyronine are associated with risk of cognitive impairment in older euthyroid adults

Highly sensitive blood-based biomarkers detection of beta-amyloid and phosphorylated-tau181 for Alzheimer's disease

Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid-β1–42 and τ Proteins as Alzheimer Disease Biomarkers

Plasma Β-Amyloid, Tau, Neurodegeneration Biomarkers and Inflammatory Factors of Probable Alzheimer's Disease Dementia in Chinese Individuals.

Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer’s disease

Changes of plasma Aβ and t-tau along with 18F-florbetapir PET in a cohort of cognitive decline

Thyroid Hormone and Alzheimer Disease: Bridging Epidemiology to Mechanism

The Role of Thyroid Function in Alzheimer's Disease

Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients

Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles

Prediction of Cerebral Amyloid Pathology Based on Plasma Amyloid and Tau Related Markers

The study on diagnostic feasibility of CSF Aβ42, T-tau, P-tau181 detection in Alzheimer dementia.

The Discriminative Capacity of CSF Β-Amyloid 42 and Tau in Neurodegenerative Diseases in the Chinese Population

A head-to-head comparison of plasma biomarkers to detect biologically defined Alzheimer in a memory clinic

Plasma Biomarker Profiles and the Association with Cognitive Function Across the Clinical Spectrum of Alzheimer's Disease